145P Neoadjuvant Chemotherapy Combined with Camrelizumab for Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Trial
K. Yang,X. Zhang,Z. Zhang,B. Wu,G. Peng,J. Huang,Q. Ding,G. Xiao,H. Ma,C. Yang,X. Xiong,L. Shi,J. Yang,X. Hong,J. Wei,Y. Qin,Y. Zhong,Y. Zhou,X. Zhao,Y. Leng
DOI: https://doi.org/10.1016/j.annonc.2021.10.164
IF: 51.769
2021-01-01
Annals of Oncology
Abstract:BackgroundStand treatment for head and neck squamous cell carcinoma (HNSCC) includes surgery, chemotherapy, and radiotherapy, which can lead to poor cosmetic and functional outcomes. PD-1 inhibitors have been tested in the neoadjuvant setting for HNSCC, which has the potential to reduce the tumor size, and lead to more limited surgery and better quality of life. This phase 2 trial investigated neoadjuvant chemotherapy combined with PD-1 inhibitor camrelizumab in patients with locally advanced HNSCC.MethodsPatients received chemotherapy (docetaxel [75 mg/m2, day 1] plus cisplatin [75 mg/m2, day 1], or nanoparticle albumin-bound paclitaxel [260 mg/m2, day 1] plus cisplatin [75 mg/m2, day 1]) and camrelizumab (200 mg, day 1) for three 21-day cycles, followed by 10-week break, surgery, and adjuvant radiotherapy. Co-primary endpoints were pathological complete response (pCR) rate and safety.ResultsFrom September 2019 to March 2021, a total of 30 patients were enrolled and completed the neoadjuvant therapy, with an objective response rate (ORR) of 96.7% and a disease control rate of 100%. Three patients refused the surgery, and 27 underwent surgery without delay, with an R0 resection rate of 92.6% (25/27). The throat and hypopharyngeal function retention rate was 84.6% (11/13). The pCR rate was 44.4% (12/27), and the major pathological response rate was 74.1% (20/27). The overall pathological downstaging rate was 100% (27/27). As of August 1, 2021, the median follow-up time was 10.5 months, and the median disease-free survival was not reached. Neoadjuvant therapy-related adverse events were all grade 1 or 2, except for a grade 3 rash reported in one patient. Regarding the surgical complications, 3 (11.1%) had intraoperative blood loss of >50 mL and 3 (11.1%) had pharyngeal leakage. No surgery-related bleeding or infection, or treatment-related death occurred.ConclusionsNeoadjuvant chemotherapy plus camrelizumab for locally advanced HNSCC showed extremely high ORR and pCR rate, and improved the rate of organ preservation, with an acceptable safety profile. This combination maybe a new treatment option for locally advanced HNSCC in the neoadjuvant setting.Clinical trial identificationThis trial is registered with ChiCTR.org.cn, number ChiCTR1900025303, on August 22, 2019.Legal entity responsible for the studyThe authors.FundingJiangsu Hengrui Pharmaceuticals Co. Ltd. provided the study drugs.DisclosureAll authors have declared no conflicts of interest. BackgroundStand treatment for head and neck squamous cell carcinoma (HNSCC) includes surgery, chemotherapy, and radiotherapy, which can lead to poor cosmetic and functional outcomes. PD-1 inhibitors have been tested in the neoadjuvant setting for HNSCC, which has the potential to reduce the tumor size, and lead to more limited surgery and better quality of life. This phase 2 trial investigated neoadjuvant chemotherapy combined with PD-1 inhibitor camrelizumab in patients with locally advanced HNSCC. Stand treatment for head and neck squamous cell carcinoma (HNSCC) includes surgery, chemotherapy, and radiotherapy, which can lead to poor cosmetic and functional outcomes. PD-1 inhibitors have been tested in the neoadjuvant setting for HNSCC, which has the potential to reduce the tumor size, and lead to more limited surgery and better quality of life. This phase 2 trial investigated neoadjuvant chemotherapy combined with PD-1 inhibitor camrelizumab in patients with locally advanced HNSCC. MethodsPatients received chemotherapy (docetaxel [75 mg/m2, day 1] plus cisplatin [75 mg/m2, day 1], or nanoparticle albumin-bound paclitaxel [260 mg/m2, day 1] plus cisplatin [75 mg/m2, day 1]) and camrelizumab (200 mg, day 1) for three 21-day cycles, followed by 10-week break, surgery, and adjuvant radiotherapy. Co-primary endpoints were pathological complete response (pCR) rate and safety. Patients received chemotherapy (docetaxel [75 mg/m2, day 1] plus cisplatin [75 mg/m2, day 1], or nanoparticle albumin-bound paclitaxel [260 mg/m2, day 1] plus cisplatin [75 mg/m2, day 1]) and camrelizumab (200 mg, day 1) for three 21-day cycles, followed by 10-week break, surgery, and adjuvant radiotherapy. Co-primary endpoints were pathological complete response (pCR) rate and safety. ResultsFrom September 2019 to March 2021, a total of 30 patients were enrolled and completed the neoadjuvant therapy, with an objective response rate (ORR) of 96.7% and a disease control rate of 100%. Three patients refused the surgery, and 27 underwent surgery without delay, with an R0 resection rate of 92.6% (25/27). The throat and hypopharyngeal function retention rate was 84.6% (11/13). The pCR rate was 44.4% (12/27), and the major pathological response rate was 74.1% (20/27). The overall pathological downstaging rate was 100% (27/27). As of August 1, 2021, the median follow-up time was 10.5 months, and the median disease-free survival was not reached. Neoadjuvant therapy-related adverse events were all grade 1 or 2, except for a grade 3 rash reported in one patient. Regarding the surgical complications, 3 (11.1%) had intraoperative blood loss of >50 mL and 3 (11.1%) had pharyngeal leakage. No surgery-related bleeding or infection, or treatment-related death occurred. From September 2019 to March 2021, a total of 30 patients were enrolled and completed the neoadjuvant therapy, with an objective response rate (ORR) of 96.7% and a disease control rate of 100%. Three patients refused the surgery, and 27 underwent surgery without delay, with an R0 resection rate of 92.6% (25/27). The throat and hypopharyngeal function retention rate was 84.6% (11/13). The pCR rate was 44.4% (12/27), and the major pathological response rate was 74.1% (20/27). The overall pathological downstaging rate was 100% (27/27). As of August 1, 2021, the median follow-up time was 10.5 months, and the median disease-free survival was not reached. Neoadjuvant therapy-related adverse events were all grade 1 or 2, except for a grade 3 rash reported in one patient. Regarding the surgical complications, 3 (11.1%) had intraoperative blood loss of >50 mL and 3 (11.1%) had pharyngeal leakage. No surgery-related bleeding or infection, or treatment-related death occurred. ConclusionsNeoadjuvant chemotherapy plus camrelizumab for locally advanced HNSCC showed extremely high ORR and pCR rate, and improved the rate of organ preservation, with an acceptable safety profile. This combination maybe a new treatment option for locally advanced HNSCC in the neoadjuvant setting. Neoadjuvant chemotherapy plus camrelizumab for locally advanced HNSCC showed extremely high ORR and pCR rate, and improved the rate of organ preservation, with an acceptable safety profile. This combination maybe a new treatment option for locally advanced HNSCC in the neoadjuvant setting.